Isoflavone treatment for 12 weeks reduced serum high-sensitivity (hs)-C-reactive protein (CRP) levels and improved brachial flow-mediated dilatation in patients with clinically manifested atherosclerosis and prior ischemic stroke [170]. This evidence concerns the gene CRP and atherosclerosis.